Heat immunotherapy with heat shock protein expression by hyperthermia using magnetite nanoparticles

Akira Ito, Takeshi Kobayashi, Hiroyuki Honda

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Hyperthermia is a possible approach for cancer therapy. However, a major technical problem associated with the use of hyperthermia is the difficulty of heating the local tumor region to the intended temperature without damaging normal tissue. Accordingly, in hyperthermia treatment, the expression of heat shock proteins (HSPs) has been considered a complicating factor because the expression of HSPs protects cells from apoptotic cell death. In cancer immunity, on the other hand, HSPs, including HSP70, have been shown to play an important role in immune reactions. If HSP expression induced by hyperthermia is involved in tumor immunity, novel cancer immunotherapy based on hyperthermia treatment can be developed. In such a strategy, a tumor-specific hyperthermia system that can induce necrotic cell death via HSP expression without damaging non-cancerous tissues would be highly advantageous. An intracellular hyperthermia system using functionalized magnetite nanoparticles, including magnetite cationic liposomes and antibody-conjugated magnetoliposomes, facilitates tumor-specific hyperthermia; this can induce necrotic cell death via HSP expression, which in turn induces antitumor immunity. We term this novel cancer therapy as "heat immunotherapy." This review discusses recent progress in cancer immunology via HSP expression and novel immunotherapy based on hyperthermia.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalAnnals of Cancer Research and Therapy
Volume15
Issue number2
DOIs
Publication statusPublished - Dec 1 2007

Fingerprint

Magnetite Nanoparticles
Heat-Shock Proteins
Immunotherapy
Fever
Hot Temperature
Neoplasms
Immunity
Cell Death
Ferrosoferric Oxide
Induced Hyperthermia
HSP70 Heat-Shock Proteins
Therapeutics
Allergy and Immunology
Liposomes
Heating

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Pharmacology (medical)

Cite this

Heat immunotherapy with heat shock protein expression by hyperthermia using magnetite nanoparticles. / Ito, Akira; Kobayashi, Takeshi; Honda, Hiroyuki.

In: Annals of Cancer Research and Therapy, Vol. 15, No. 2, 01.12.2007, p. 27-34.

Research output: Contribution to journalReview article

@article{4b428d2f30e24bbab00e9393e109e745,
title = "Heat immunotherapy with heat shock protein expression by hyperthermia using magnetite nanoparticles",
abstract = "Hyperthermia is a possible approach for cancer therapy. However, a major technical problem associated with the use of hyperthermia is the difficulty of heating the local tumor region to the intended temperature without damaging normal tissue. Accordingly, in hyperthermia treatment, the expression of heat shock proteins (HSPs) has been considered a complicating factor because the expression of HSPs protects cells from apoptotic cell death. In cancer immunity, on the other hand, HSPs, including HSP70, have been shown to play an important role in immune reactions. If HSP expression induced by hyperthermia is involved in tumor immunity, novel cancer immunotherapy based on hyperthermia treatment can be developed. In such a strategy, a tumor-specific hyperthermia system that can induce necrotic cell death via HSP expression without damaging non-cancerous tissues would be highly advantageous. An intracellular hyperthermia system using functionalized magnetite nanoparticles, including magnetite cationic liposomes and antibody-conjugated magnetoliposomes, facilitates tumor-specific hyperthermia; this can induce necrotic cell death via HSP expression, which in turn induces antitumor immunity. We term this novel cancer therapy as {"}heat immunotherapy.{"} This review discusses recent progress in cancer immunology via HSP expression and novel immunotherapy based on hyperthermia.",
author = "Akira Ito and Takeshi Kobayashi and Hiroyuki Honda",
year = "2007",
month = "12",
day = "1",
doi = "10.4993/acrt.15.27",
language = "English",
volume = "15",
pages = "27--34",
journal = "Annals of Cancer Research and Therapy",
issn = "1344-6835",
publisher = "PJD Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Heat immunotherapy with heat shock protein expression by hyperthermia using magnetite nanoparticles

AU - Ito, Akira

AU - Kobayashi, Takeshi

AU - Honda, Hiroyuki

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Hyperthermia is a possible approach for cancer therapy. However, a major technical problem associated with the use of hyperthermia is the difficulty of heating the local tumor region to the intended temperature without damaging normal tissue. Accordingly, in hyperthermia treatment, the expression of heat shock proteins (HSPs) has been considered a complicating factor because the expression of HSPs protects cells from apoptotic cell death. In cancer immunity, on the other hand, HSPs, including HSP70, have been shown to play an important role in immune reactions. If HSP expression induced by hyperthermia is involved in tumor immunity, novel cancer immunotherapy based on hyperthermia treatment can be developed. In such a strategy, a tumor-specific hyperthermia system that can induce necrotic cell death via HSP expression without damaging non-cancerous tissues would be highly advantageous. An intracellular hyperthermia system using functionalized magnetite nanoparticles, including magnetite cationic liposomes and antibody-conjugated magnetoliposomes, facilitates tumor-specific hyperthermia; this can induce necrotic cell death via HSP expression, which in turn induces antitumor immunity. We term this novel cancer therapy as "heat immunotherapy." This review discusses recent progress in cancer immunology via HSP expression and novel immunotherapy based on hyperthermia.

AB - Hyperthermia is a possible approach for cancer therapy. However, a major technical problem associated with the use of hyperthermia is the difficulty of heating the local tumor region to the intended temperature without damaging normal tissue. Accordingly, in hyperthermia treatment, the expression of heat shock proteins (HSPs) has been considered a complicating factor because the expression of HSPs protects cells from apoptotic cell death. In cancer immunity, on the other hand, HSPs, including HSP70, have been shown to play an important role in immune reactions. If HSP expression induced by hyperthermia is involved in tumor immunity, novel cancer immunotherapy based on hyperthermia treatment can be developed. In such a strategy, a tumor-specific hyperthermia system that can induce necrotic cell death via HSP expression without damaging non-cancerous tissues would be highly advantageous. An intracellular hyperthermia system using functionalized magnetite nanoparticles, including magnetite cationic liposomes and antibody-conjugated magnetoliposomes, facilitates tumor-specific hyperthermia; this can induce necrotic cell death via HSP expression, which in turn induces antitumor immunity. We term this novel cancer therapy as "heat immunotherapy." This review discusses recent progress in cancer immunology via HSP expression and novel immunotherapy based on hyperthermia.

UR - http://www.scopus.com/inward/record.url?scp=76149091909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149091909&partnerID=8YFLogxK

U2 - 10.4993/acrt.15.27

DO - 10.4993/acrt.15.27

M3 - Review article

VL - 15

SP - 27

EP - 34

JO - Annals of Cancer Research and Therapy

JF - Annals of Cancer Research and Therapy

SN - 1344-6835

IS - 2

ER -